ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: L01

Impact of Glucocorticoid Dosing and Anti-Osteoporotic Treatment on Bone Health in Patients with Inflammatory Rheumatic Musculoskeletal Diseases: A Longitudinal Cohort Study
Abstract Number: 0828

Impact of Hospitalization on Clinical Outcomes in Patients with Connective Tissue Disease-associated Interstitial Lung Disease
Abstract Number: 0984

Impact of Hydroxychloroquine on Interferon Pathway Expression of SLE Phenotypic Subsets in the Absence of Background Medications
Abstract Number: 0925

Impact of Initiating Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs on Pain Medication Use in Patients with Rheumatoid Arthritis
Abstract Number: 2249

Impact of Interstitial Lung Disease on COVID-19 Severity Among Patients with Rheumatoid Arthritis: A Multicenter Comparative Study
Abstract Number: 1812

Impact of Misclassification on the US Prevalence of Gout: Bayesian Sensitivity Analysis of the National Health & Nutrition Examination Survey (NHANES)
Abstract Number: 0099

Impact of Multimodal Independent Medical Education on Improving Outcomes and Reducing Disparities in Systemic Lupus Erythematosus and Lupus Nephritis
Abstract Number: 1227

Impact of Pain Sensitivity and Expectations on Predicting Response to Acupuncture in Fibromyalgia
Abstract Number: 2137

Impact of Patient Characteristics, Including Sex, on the Efficacy of Upadacitinib Compared with Adalimumab in Patients with Psoriatic Arthritis
Abstract Number: 0156

Impact of Polymyositis and Dermatomyositis in Patients Admitted with Congestive Heart Failure: An Insight from the National Database
Abstract Number: 0102

Impact of Racial Implicit Bias on Juvenile Idiopathic Arthritis Patients’ Treatment Recommendations
Abstract Number: 2126

Impact of Risankizumab on Enthesitis and Dactylitis: Integrated Analysis of the Phase 3, Randomized, Double-Blind KEEPsAKE 1 and 2 Trials
Abstract Number: 1363

Impact of SARS-CoV-2 on the Clinical Presentation of Juvenile Idiopathic Inflammatory Myopathies
Abstract Number: 0934

Impact of Tapering Targeted Therapy on Disease Activity Is Different Based on Concomitant Methotrexate Use in Patients with Rheumatoid Arthritis: A Nationwide Cohort Study
Abstract Number: 0082

Impact of the COVID-19 Pandemic on Healthcare Utilization Among Rheumatoid Arthritis, Psoriatic Arthritis and Systemic Lupus Erythematosus Patients

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].